Evidence map›Paper›PMID 20705914›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2010

FRNK inhibition of focal adhesion kinase-dependent signaling and migration in vascular smooth muscle cells.

Yevgeniya E Koshman, Taehoon Kim, Miensheng Chu, Steven J Engman, Rekha Iyengar, Seth L Robia, Allen M Samarel

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. FAK Family Kinases in Vascular Diseases.International journal of molecular sciences · 2020
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yevgeniya E KoshmanCardiovascular Institute, Loyola University Medical Center, 2160 S First Ave, Maywood, IL 60153, USA.
Taehoon Kim
Miensheng Chu
Steven J Engman
Rekha Iyengar
Seth L Robia
Allen M Samarel
Loyola University Medical Center · US

Funding

Structural Determinants of Calcium Pump RegulationR01HL092321 · NHLBI · LOYOLA UNIVERSITY CHICAGO · PI Seth L Robia · 2008 to 2026
$8.9M
Novel Physical Methods for Determining Membrane Protein Dynamics and KineticsK01EB006061 · NIBIB · LOYOLA UNIVERSITY CHICAGO · PI ROBIA, SETH L · 2007 to 2011
$772k
NHLBI NIH HHS R01 HL092321NIBIB NIH HHS K01 EB006061
6 · The paper itself

Abstract

objectiveTo examine whether interference with FRNK targeting to focal adhesions (FAs) affects its inhibitory activity and tyrosine phosphorylation. METHODS AND

resultsFocal adhesion kinase and its autonomously expressed C-terminal inhibitor, focal adhesion kinase-related nonkinase (FRNK), regulate vascular smooth muscle cell (VSMC) signaling and migration. FRNK-paxillin binding was reduced by a point mutation in its FA targeting domain (L341S-FRNK). Green fluorescent protein-tagged wild type and L341S-FRNK were then adenovirally expressed in VSMCs. L341S-FRNK targeted to VSMC FAs, despite previous studies in other cell types. L341S-FRNK affected FA binding kinetics (assessed by total internal reflection fluorescnece [TIRF] microscopy and fluorescence recovery after photobleaching [FRAP]) and reduced its steady-state paxillin interaction (determined by coimmunoprecipitation). Both wt-FRNK and L341S-FRNK lowered basal and angiotensin II-stimulated focal adhesion kinase, paxillin, and extracellular signal-regulated kinase 1/2 phosphorylation. However, the degree of inhibition was significantly reduced by L341S-FRNK. L341S-FRNK also demonstrated significantly greater migratory activity compared with wt-FRNK-expressing VSMCs. Angiotensin II-induced Y168 phosphorylation was Src dependent, as evident by a significant reduction in Y168 phosphorylation by the Src family kinase inhibitor PP2 is 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). Surprisingly, Y168 phosphorylation was unaffected by its targeting. Furthermore, Y232 phosphorylation increased approximately 3-fold in L341S-FRNK, which was less sensitive to PP2.

conclusionsFRNK inhibition of VSMC migration requires both FA targeting and Y168 phosphorylation by Src family kinases. FRNK-Y232 phosphorylation occurs outside of FAs, probably by a PP2-insensitive kinase.

Indexed as

AnimalsCell MovementFocal Adhesion Protein-Tyrosine KinasesMuscle, Smooth, VascularMyocytes, Smooth MusclePaxillinPhosphorylationPoint MutationProtein-Tyrosine KinasesRatsSignal TransductionFAK-related nonkinaseFocal Adhesion Protein-Tyrosine KinasesPaxillinProtein-Tyrosine Kinases

Identifiers

PMID20705914
PMCPMC4058887
OpenAlexW2102125023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.